Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 3/20 | 0.77 |
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.68 |
| ▸ | LMNA | P02545 | 6/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.68 |
| ▸ | SHBG | P04278 | 3/20 | 0.68 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.68 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.68 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1418766 | 1.00 | G6PD (0.77) | G6PDGPBAR1LMNACYP3A4SHBG | |
| SCHEMBL1418928 | 1.00 | G6PD (0.77) | G6PDGPBAR1LMNACYP3A4SHBG | |
| SCHEMBL6874636 | 1.00 | G6PD (0.77) | G6PDGPBAR1LMNACYP3A4SHBG | |
| SCHEMBL1418641 | 1.00 | G6PD (0.77) | G6PDGPBAR1LMNACYP3A4SHBG | |
| SCHEMBL6905401 | 1.00 | G6PD (0.77) | G6PDGPBAR1LMNACYP3A4SHBG | |
| SCHEMBL1418980 | 1.00 | G6PD (0.77) | G6PDGPBAR1LMNACYP3A4SHBG | |
| SCHEMBL6884657 | 1.00 | G6PD (0.77) | G6PDGPBAR1LMNACYP3A4SHBG | |
| SCHEMBL1418644 | 1.00 | G6PD (0.77) | G6PDGPBAR1LMNACYP3A4SHBG | |
| SCHEMBL1500304 | 1.00 | G6PD (0.77) | G6PDGPBAR1LMNACYP3A4SHBG | |
| SCHEMBL1418792 | 1.00 | G6PD (0.77) | G6PDGPBAR1LMNACYP3A4SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539183-A4 | THERAPEUTIC TREATMENT METHODS | HOLLIS EDEN PHARMACEUTICALS (US) | 2007-04-25 | — | — | EP | claimed |
| US-20050256095-A1 | Asthma and colitis treatment methods | BIOVIE INC. | 2005-11-17 | — | — | US | claimed |
| EP-1539183-A1 | THERAPEUTIC TREATMENT METHODS | Hollis-Eden Pharmaceuticals Inc. (US) | 2005-06-15 | — | — | EP | claimed |
| US-20050101581-A1 | Therapeutic treatment methods 2 | BIOVIE INC. | 2005-05-12 | — | — | US | claimed |
| US-20050075321-A1 | Neurological disorder treatment methods | BIOVIE INC. | 2005-04-07 | — | — | US | claimed |
| US-20040138187-A1 | Therapeutic treatment methods | BIOVIE INC. | 2004-07-15 | — | — | US | claimed |
| WO-2004019953-A1 | THERAPEUTIC TREATMENT METHODS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2004-03-11 | — | — | WO | claimed |
| US-20150353596-A1 | 17-Substituted Steroid Compounds | HOLLIS-EDEN PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9115168-B2 | Steroids having 7-oxygen and 17-heteroaryl substitution-3 | NEURMEDIX, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9102702-B2 | Steroids having 7-oxygen and 17-heteroaryl substitution-2 | NEURMEDIX INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20140018336-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-2 | Harbor Therapeutics, Inc. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018337-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-3 | Harbor Therapeutics, Inc. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8569275-B2 | Steroids having 7-oxgen and 17-heteroaryl substitution | Harbor Therapeutics, Inc. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20060073099-A1 | Treatment screening methods | BIOVIE INC. | 2006-04-06 | — | — | US | disclosed |
| EP-1539183-A1 | THERAPEUTIC TREATMENT METHODS | Hollis-Eden Pharmaceuticals Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050101581-A1 | Therapeutic treatment methods 2 | BIOVIE INC. | 2005-05-12 | — | — | US | disclosed |
| US-20040138187-A1 | Therapeutic treatment methods | BIOVIE INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2004019953-A1 | THERAPEUTIC TREATMENT METHODS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| US-6274118-B1 | INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE | NORDION INTERNATIONAL INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353596-A1 | 17-Substituted Steroid Compounds | HSD3B1, HSD3B2, HSD17B13 | G6PD 319/4885GPBAR1 216/4885LMNA 3127/4885 |
| US-20140018336-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-2 | HSD3B1, HSD3B2, HSD17B13 | G6PD 322/4885GPBAR1 295/4885LMNA 3602/4885 |
| US-20050075321-A1 | Neurological disorder treatment methods | HSD17B1, HSD17B3, HSD3B1 | G6PD 647/4885GPBAR1 649/4885LMNA 3357/4885 |
| US-20140018337-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-3 | HSD3B1, HSD3B2, HSD17B13 | G6PD 320/4885GPBAR1 289/4885LMNA 3560/4885 |
| US-20060073099-A1 | Treatment screening methods | HSD17B11, HSD3B2, HSD3B1 | G6PD 241/4885GPBAR1 901/4885LMNA 1231/4885 |
| US-20050101581-A1 | Therapeutic treatment methods 2 | HSD3B2, HSD3B1, HSD17B2 | G6PD 252/4885GPBAR1 187/4885LMNA 2777/4885 |
| US-20050256095-A1 | Asthma and colitis treatment methods | HSD3B1, HSD17B1, HSD11B1 | G6PD 768/4885GPBAR1 138/4885LMNA 4427/4885 |
| US-20040138187-A1 | Therapeutic treatment methods | ELANE, ALOX15, IL15 | G6PD 362/4885GPBAR1 244/4885LMNA 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.